HLS Therapeutics
Manufacturing · Canada · 51-200 Employees
View Company Info for Free
Overview
Headquarters
10 Carlson Crt Suite 701, Etobicoke, Ont...Phone Number
(484) 232-3400Website
www.hlstherapeutics.comRevenue
$60.8 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About HLS Therapeutics
HLS Therapeutics, founded in 2015, is a specialty pharmaceutical company that acquires and commercializes branded pharmaceutical products in North America. The company specializes in medications targeting central nervous system and cardiovascular therapeutic areas. Based in Canada with multiple locations across North America, HLS Therapeutics focuses on late-stage development, commercial-stage, and established pharmaceutical products. The company operates with both business-to-business and business-to-consumer models, offering pharmaceutical solutions through retail pharmacy channels. As a publicly traded company, HLS Therapeutics continues to expand its portfolio of specialized medications to address critical health needs.Explore more
HLS Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is HLS Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on HLS Therapeutics recently announced quarterly report
Website visits: Recent activity has been detected on your website
HLS Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if HLS Therapeutics had a recent Job posting/layoffs
Check if HLS Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at HLS Therapeutics
Product Launch: Get notified when HLS Therapeutics launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if HLS Therapeutics is spiking on competitors!
Funding: Get notified immidiatlly once HLS Therapeutics has new funding data
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to HLS Therapeutics
Compare insights from companies similar to HLS Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
$18M
51-200
Private
-
1999
GC
Gaël ClercSenior VP, Product Development Engineering, B Research Solution For Clinical Trial & Rwe
Company Profile Activity
Activity Insights
HLS Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
HLS Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about HLS Therapeutics.
HLS Therapeutics Tech Stack
Most Recent Scoops
Person-Based
Earnings, Forecasting, Finance
Person-Based
Craig Millian participated in the company Q1 2026 financial results conference call on May 15, 2026.
Earnings, Finance
Person-Based
Person-Based
Person-Based
HLS Therapeutics News & Media
HLS Therapeutics Inc. (HLS:CA) Shareholder/Analyst Call Prepared Remarks Transcript
HLS Therapeutics Inc. (HLS:CA) Shareholder/Analyst Call June 26, 2026 10:00 AM EDTCompany ParticipantsRyan Lennox - Senior VP of Legal, HR & Compliance...HLS Therapeutics Q1 Earnings Call Highlights
HLS Therapeutics (TSE:HLS) reported modest first-quarter revenue growth and reaffirmed its 2026 outlook, while management highlighted early momentum for the company’s newly launched cholesterol drug NILEMDO and continued deleveraging of its balance sheet. On a conference call discussing results forHLS Therapeutics Q4 Earnings Call Highlights
HLS Therapeutics (TSE:HLS) reported fourth-quarter and full-year 2025 results on Thursday, highlighting adjusted EBITDA growth, reduced leverage, and preparations for the Canadian launch of NILEMDO as the company works to expand its cardiovascular franchise. 2025 results: adjusted EBITDA growth andHLS Therapeutics Inc. (HLS:CA) Q4 2025 Earnings Call Transcript
HLS Therapeutics Inc. (HLS:CA) Q4 2025 Earnings Call March 12, 2026 8:30 AM EDTCompany ParticipantsDave Mason - Investor Relations OfficerCraig Millian -...
Read more news
Top Manufacturing Companies
Top companies in New Zealand by revenue
Top companies in United Kingdom by revenue
Frequently Asked Questions Regarding HLS Therapeutics
Sign Up For FreeTo access detailed company insights
HLS Therapeutics, founded in 2015, is a specialty pharmaceutical company that acquires and commercializes branded pharmaceutical products in North America. The company specializes in medications targeting central nervous system and cardiovascular therapeutic areas. Based in Canada with multiple locations across North America, HLS Therapeutics focus... Read More
